8th Annual Biomarker and Companion Diagnostics Conference: Leveraging Next-Gen Technologies Beyond Conventional Biomarker Drug Discovery (San Diego, United States - February 8-9, 2023) - ResearchAndMarkets.com

2022-12-13

DUBLIN--(BUSINESS WIRE)--The "8th Annual Biomarker and Companion Diagnostics Conference" conference has been added to ResearchAndMarkets.com's offering.

'8th Annual Biomarker and Companion Diagnostics Conference'

Leveraging next-gen technologies beyond conventional biomarker drug discovery!

The hosts bring to you the 8th Annual Biomarker and CDx Conference scheduled to be held on 8th - 9th February 2023 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.

30+ experts from academia and industry will be presenting their current work in Biomarkers, the latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, the Impact of Big data in translational biomarker research and the Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

What To Expect

Key Highlights

Commercialization of CDx

Proteomics and Genomics based Biomarkers

Biomarker Drug Discovery and Assay Development

Multiplex Companion Diagnostics and Regulatory Guidelines

Design of clinical trials in CDx

Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data

Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Who Should Attend:

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development

Translational research

Clinical Biomarker

Biomarkers in IO and Neurological disorders

Imaging Biomarkers

Pathology

Companion Diagnostics

Biomarker Imaging

Proteomics Biomarkers

Experimental Medicine

Data Science

Biomarkers in Clinical Discovery

Immuno-oncology/Neuroscience Drug Discovery

Diagnostic Biomarkers development

Personalized Medicine

Immunology Biomarkers

Agenda:

Day 1 Wed, 08-Feb-2023

Registration

08:15 - 08:45

Welcome note

08:45 - 09:05

Opening Remarks from the Chairman

09:05 - 09:10

Keynote Presentation

09:10 - 09:40

Challenges associated with Clinical Biomarker Validation

Advancing Digital Pathology in biomarker identification and drug discovery

09:40 - 10:10

Solution Provider Presentation-Reserved for Gold Sponsor

10:10 - 10:25

Morning Refreshments and Poster Presentation - One-to-One Networking Meetings

10:25 - 11:10

Non-invasive biomarker identification and analysis using Breath Biopsy

11:10 - 11:40 Huw Davies, VP, Global Sales, Owlstone Medical

Presentation by BD Biosciences

11:40 - 12:10

Studying the clinical change of paradigm in liquid biopsies

12:10 - 12:40

Use of biomarkers in clinics-success and challenges of getting a good biomarker

12:40 - 13:10

Lunch and Poster Presentation - One-to-One Networking Meetings

13:10 - 14:10

Role of Biomarkers in Personalized Medicine

Precision Oncology Centric Development of Antibody Drug Conjugates

14:10 - 14:40 Rakesh Dixit, CEO, Bionavigen

Solution Provider Presentation

14:40 - 14:55

Why is monitoring predictive biomarker data so difficult for big pharma?

14:55 - 15:25

AI for proteomics and biomarker discovery

15:25 - 15:55

Afternoon Refreshments and Poster Presentation - One-to-One Networking Meetings

15:55 - 16:40

Patient Identification and Stratification applying predictive models

16:40 - 17:10

Use of Real World Evidence in the discovery of digital biomarkers

17:10 - 17:25

Solution Provider Presentation

17:25 - 17:55

Closing Remarks from the Chairman

17:55 - 17:55

Drinks Reception & Networking

17:55 - 17:55

End of Day 1

17:55 - 17:55

Day 2 Thu, 09-Feb-2023

Registration

08:15 - 09:00

Welcome note

09:00 - 09:05

Opening Remarks from the Chairman

09:05 - 09:10

Keynote Presentation

09:10 - 09:40

From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization

From Undruggable Target to CDx and Beyond

09:40 - 10:10 Mason Israel, Regional Medical Affairs Director, Mirati Therapeutics

Solution Provider Presentation-Reserved for Gold Sponsor

10:10 - 10:25

Morning Refreshments and Poster Presentation - One-to-One Networking Meetings

10:25 - 11:10

Future of RNA Diagnostics in Cancer

11:10 - 11:40 Michael Milburn, President, CEO, GeneCentric Therapeutics

Solution Provider Presentation-Reserved for Silver Sponsor

11:40 - 11:55

CDx Launch Success: From Early Biomarker Development to Commercialization

11:55 - 12:10

Solution Provider Presentation

12:10 - 12:40

Building up a successful CDx partnership with Pharma

12:40 - 13:10

Lunch and Poster Presentation - One-to-One Networking Meetings

13:10 - 14:10

Clinical Applications of Biomarkers in Immuno-Oncology, Neurology, and Infectious Diseases

Solution Provider Presentation

14:10 - 14:25

Leveraging IO markers for companion diagnostics development

14:25 - 14:55

Solution Provider Presentation

14:55 - 15:25

Innovative Safety Biomarker Applications to Drug Development

15:25 - 15:55

End of Conference

15:55 - 15:55

Speakers

Maria Wang

Associate Director, Bristol-Myers Squibb

Yingpeng Zhan

Scientist, Sorrento Therapeutics

Michael Milburn

President, CEO, GeneCentric Therapeutics

Rakesh Dixit

CEO, Bionavigen

Mason Israel

Regional Medical Affairs Director, Mirati Therapeutics

Matthew Davis

Director, Molecular Biology and Sequencing, Gritstone Oncology

Huw Davies

VP, Global Sales, Owlstone Medical

Senior Representative, BD Biosciences

For more information about this conference visit https://www.researchandmarkets.com/r/lwpsu7